Brenna C Simons1, Philip R Spradling2, Dana J T Bruden3, Carolyn Zanis3, Samantha Case3, Tammy L Choromanski4, Minjun Apodaca5, Hazel D Brogdon6, Gaelen Dwyer6, Mary Snowball4, Susan Negus4, Michael G Bruce3, Chihiro Morishima5, Cindy Knall6, Brian J McMahon7. 1. Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC) WWAMI School of Medical Education, College of Health, University of Alaska Anchorage. 2. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, Georgia. 3. Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC). 4. Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium. 5. Department of Laboratory Medicine, University of Washington, Seattle. 6. WWAMI School of Medical Education, College of Health, University of Alaska Anchorage. 7. Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC).
Abstract
BACKGROUND: Long-lasting protection resulting from hepatitis B vaccine, despite loss of antibody against hepatitis B virus (HBV) surface antigen (anti-HBs), is undetermined. METHODS: We recruited persons from a cohort vaccinated with plasma-derived hepatitis B vaccine in 1981 who have been followed periodically since. We performed serological testing for anti-HBs and microRNA-155 and assessed HBV-specific T-cell responses by enzyme-linked immunospot and cytometric bead array. Study subgroups were defined 32 years after vaccination as having an anti-HBs level of either ≥10 mIU/mL (group 1; n = 13) or <10 mIU/mL (group 2; n = 31). RESULTS: All 44 participants, regardless of anti-HBs level, tested positive for tumor necrosis factor α, interleukin 10, or interleukin 6 production by HBV surface antigen-specific T cells. The frequency of natural killer T cells correlated with the level of anti-HBs (P = .008). The proportion of participants who demonstrated T-cell responses to HBV core antigen varied among the cytokines measured, suggesting some natural exposure to HBV in the study group. No participant had evidence of breakthrough HBV infection. CONCLUSIONS: Evidence of long-lasting cellular immunity, regardless of anti-HBs level, suggests that protection afforded by primary immunization with plasma-derived hepatitis B vaccine during childhood and adulthood lasts at least 32 years.
BACKGROUND: Long-lasting protection resulting from hepatitis B vaccine, despite loss of antibody against hepatitis B virus (HBV) surface antigen (anti-HBs), is undetermined. METHODS: We recruited persons from a cohort vaccinated with plasma-derived hepatitis B vaccine in 1981 who have been followed periodically since. We performed serological testing for anti-HBs and microRNA-155 and assessed HBV-specific T-cell responses by enzyme-linked immunospot and cytometric bead array. Study subgroups were defined 32 years after vaccination as having an anti-HBs level of either ≥10 mIU/mL (group 1; n = 13) or <10 mIU/mL (group 2; n = 31). RESULTS: All 44 participants, regardless of anti-HBs level, tested positive for tumor necrosis factor α, interleukin 10, or interleukin 6 production by HBV surface antigen-specific T cells. The frequency of natural killer T cells correlated with the level of anti-HBs (P = .008). The proportion of participants who demonstrated T-cell responses to HBV core antigen varied among the cytokines measured, suggesting some natural exposure to HBV in the study group. No participant had evidence of breakthrough HBV infection. CONCLUSIONS: Evidence of long-lasting cellular immunity, regardless of anti-HBs level, suggests that protection afforded by primary immunization with plasma-derived hepatitis B vaccine during childhood and adulthood lasts at least 32 years.
Authors: Brenna C Simons; Scott E Vancompernolle; Rita M Smith; Jie Wei; Louise Barnett; Shelly L Lorey; Dirk Meyer-Olson; Spyros A Kalams Journal: J Immunol Date: 2008-10-01 Impact factor: 5.422
Authors: Brian J McMahon; Lisa R Bulkow; Rosalyn J Singleton; James Williams; Mary Snowball; Chriss Homan; Alan J Parkinson Journal: Hepatology Date: 2011-07-19 Impact factor: 17.425
Authors: J L Williams; C J Christensen; B J McMahon; L R Bulkow; H H Cagle; J S Mayers; C L Zanis; A J Parkinson; H S Margolis Journal: Vaccine Date: 2001-07-16 Impact factor: 3.641
Authors: Ryan M McAdams; Craig J Bierle; Erica Boldenow; Samantha Weed; Jesse Tsai; Richard P Beyer; James W MacDonald; Theo K Bammler; H Denny Liggitt; Federico M Farin; Jeroen Vanderhoeven; Lakshmi Rajagopal; Kristina M Adams Waldorf Journal: Infect Immun Date: 2015-07-20 Impact factor: 3.441
Authors: Taraz Samandari; Anthony E Fiore; Susan Negus; James L Williams; Wendi Kuhnert; Brian J McMahon; Beth P Bell Journal: Pediatrics Date: 2007-07-16 Impact factor: 7.124
Authors: Sylvia M Kiertscher; Pallavi R Gangalum; Grace Ibrahim; Donald P Tashkin; Michael D Roth Journal: J Neuroimmune Pharmacol Date: 2018-01-16 Impact factor: 4.147
Authors: Timo Vesikari; Jin Xu; David R Johnson; Jessie Hall; Tomáš Marček; Michelle G Goveia; Camilo J Acosta; Andrew Wen-Tseng Lee Journal: Hum Vaccin Immunother Date: 2019-11-05 Impact factor: 3.452
Authors: Pierre Van Damme; Marc Dionne; Geert Leroux-Roels; Olivier Van Der Meeren; Emmanuel Di Paolo; Bruno Salaun; Pemmaraju Surya Kiran; Nicolas Folschweiller Journal: J Viral Hepat Date: 2019-06-02 Impact factor: 3.728
Authors: Sarah Schillie; Claudia Vellozzi; Arthur Reingold; Aaron Harris; Penina Haber; John W Ward; Noele P Nelson Journal: MMWR Recomm Rep Date: 2018-01-12